AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Strategic Partners A/S

Interim / Quarterly Report Sep 16, 2025

3411_ir_2025-09-16_c0bbfc2a-6d30-468f-958a-3e9c7191aa96.pdf

Interim / Quarterly Report

Open in Viewer

Opens in native device viewer

Strategic Partners A/S Lyskær 8A DK-2730 Herlev www.strategic-partners.com CVR No.: 32266355

Interim Report First Half 2025

Strategic Partners A/S (the "Company"), today announces its Interim Report First Half 2025 for the period January 1 – June 30, 2025.

Financial highlights First Half 2025

The total comprehensive profit/loss for the first half 2025 was a net loss of DKK 1.2 million compared to a total comprehensive profit of DKK 1.8 million for the same period in 2024.

Operating expenses for the six months ended June 30, 2024 totaled DKK 1.4 million compared to DKK 1.5 million for the same period in 2024.

In January 2025 the Company sold its strategic position in CombiGene AB for a price close to the acquisition cost. The investment in CombiGene AB contributed with a net profit of DKK 0.4 million until the sale in January.

The result from property investments and securities is reported as other income and is realized at a net gain DKK 0.1 million.

The Company is in the final process to liquidate its subsidiaries in US and Switzerland and expect that the liquidation will be finalized in 2025. Following these liquidations, the Company will only consist of the Danish parent company.

Management's review and Business update

In continuation of the strategy, it is still the Company's wish to continue investing and adding competences in new partnerships in order to create added value for the Company's shareholders, as well as to attract additional capital to the company via capital raisings or the purchase of companies/assets via the issue of new shares in order to gain a greater critical mass.

Risk and uncertainties

For information on risks and uncertainties relating to Orphazyme's business please refer to our Statutory Annual Report 2024. Additional risks and uncertainties, including risks that are not known to the Company at present or that its management currently deems immaterial or nonspecific to the Company, may also arise or become material or specific to the Company in the future, which could, if such risks were to materialize, have a material and adverse effect on the Company's business, financial condition, and/or results of operations.

Subsequent Events

Management is not aware of any events subsequent to 30 June 2025 which could be expected to have a significant impact on the group's financial position.

Outlook

Based on the first half of the year the company changes its outlook from previously an operating loss in the range of DKK -3 to -4 million to DKK -2 to -3 million .

Forward-looking statements, in particular relating to future activities, operating income and expenses as well as other key financials, are subject to risks and uncertainties. Various factors, many of which lie outside of the Company's control, may cause the realized results to differ materially from the expectations presented in this earnings release.

Condensed Key Figures

As of and for As of and for As of and for the
DKK (000) the six the six-months year
months ended ended Jun 30, ended Dec
Jun 30, 2025 2024 31, 2024
Statement of profit or loss
General and administrative expenses (1,448) (1,492) (2,897)
Other income and expenses 57 3,186 2,696
Operating profit/(loss) (1,391) 1,694 (201)
Net financial items 204 154 (97)
Total comprehensive income (loss) (1,187) 1,848 (298)
Profit / (loss) per share, basic (DKK) (28) 52 (8)
Profit / (loss) per share, diluted (DKK) (28) 52 (8)
Statement of financial position
Investment property 3,573 - 3,550
Cash 3,222 13,973 3,886
Securities 12,053 3,781 16,086
Other current assets 2 97 36
Total assets 18,850 17,850 23,558
Share capital 6,257 5,297 6,257
Total equity 18,061 16,089 19,248
Current liabilities 789 1,761 4,310
Cash flow statement
Net cash from operating activities (4,628) (289) (3,361)
Net cash from investing activities 3,964 2,993 (9,327)
Net cash from financing activities - - 5,306
Other
Share price (DKK) 1,000 968 825
Total outstanding shares 41,712 35,312 41,712
Market capitalization (DKK million) 41.7 34.2 34.4
Equity ratio 96% 85% 82%
Equity per share (DKK) 433 427 461

Statement of Profit or Loss and Other Comprehensive Income

Twelve
Six months Six months months
ended ended ended
Jun 30, 2025 Jun 30, 2024 Dec 31, 2024
DKK (000) DKK (000) DKK (000)
General and administrative expenses (1,448) (1,492) (2,897)
Other income and expenses 57 3,186 2,696
Operating result (1,391) 1,694 (201)
Financial items, net 204 154 (97)
Total comprehensive income (loss) 1,187 1,848 (298)
Profit/(loss) per share, basic (28) 52 (8)
Profit/(loss) per share, diluted (28) 52 (8)

Statement of Financial position

Jun 30, 2025 Jun 30, 2024 Dec 31, 2024
DKK (000) DKK (000) DKK (000)
ASSETS
Fixed assets
Investment property 3,573 - 3,550
Total fixed assets 3,573 - 3,550
Current assets
Prepayments and other receivables 2 96 36
Securities and partnerships 12,053 3,781 16,086
Cash 3,222 13,973 3,886
Total current assets 15,277 17,850 20,008
TOTAL ASSETS 18,850 17,850 23,558
EQUITY & LIABILITIES
Equity
Share capital 6,257 5,297 6,257
Other reserves - 6,987 -
Retained earnings 11,804 3,806 12,991
Total equity 18,061 16,089 19,248
Current liabilities
Trade payable and accruals 789 1,761 4,310
Total current liabilities 789 1,761 4,310
TOTAL EQUITY AND LIABILITIES 18,850 17,850 23,558

Statement of Changes in Shareholders' Equity

DKK (000) Share capital Other
reserves
Accumulated
deficit
Total
Balance as of Dec 31, 2023 12,283 - 1,959 14,242
Capital reduction (6,986) 6,986 - -
Net loss for the period - - 1,847 1,847
Balance as of June 30, 2024 5,297 6,986 3,806 16,089
Balance as of Dec 31, 2024 6,257 - 12,991 19,248
Net profit for the period - - (1,187) (1,187)
Balance as of June 30, 2024 6,257 - 11,804 18,061

Cash Flow Statement

Six months ended Six months ended
Jun 30, 2025 Jun 30, 2024
DKK (000) DKK (000)
Operating activities
Operating profit / (loss) (1,391) 1,694
Investment result, non cash 46 170
Change in receivables 34 1,002
Change in accruals and other liabilities (3,521) (3,309)
Interest received / (paid), net 204 154
Cash flow from operating activities (4,628) (289)
Investing activities
Purchase of securities - (2,963)
Sale of securities 3,987 5,956
Investment property (23) -
Cash flow from investment activities 3,964 2,993
Changes in cash and cash equivalents (664) 2,704
Cash balance at beginning of period 3,886 11,269
Cash balance at end of period 3,222 13,973

Notes to the Interim Financial Statement

NOTE 1 – CORPORATE INFORMATION

Strategic Partners A/S is headquartered in Copenhagen, Denmark and is publicly traded on Nasdaq Copenhagen.

The Company is in the process of the final liquidation of the subsidiaries in US and Switzerland.

There were no material related party transactions during the first half of 2025 other than remuneration to the Executive Management and the Board of Directors.

Basis of preparation

The interim condensed financial statements for the six months ended June 30, 2025 have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the International Accounting Standards Board (IASB) and as adopted by the EU, and additional Danish disclosure requirements for interim reports of companies listed on the Nasdaq Copenhagen.

The interim condensed financial statements do not include all the information and disclosures required in annual financial statements and should be read in conjunction with the Company's latest annual financial statements as of December 31, 2024. These interim condensed financial statements have been prepared in accordance with the going concern assumption.

Updates to the Group's accounting policies

The accounting policies used in the preparation of the interim condensed financial statements are consistent with those used in the preparation of Strategic Partners A/S's annual financial statements for the year ended December 31, 2024.

The interim financial report has not been reviewed or audited by the Company's independent auditors.

Significant accounting estimates and judgements

The significant accounting estimates and judgements disclosed in note 1.4 of the financial statements for the year ended December 31, 2024 are still applicable.

NOTE 2 –INVESTMENT IN PARTNERSHIPS AND INVESTMENT PROPERTY

In January 2025 the Company sold the position in CombiGene AB for a price close to the acquisition cost.

The Company is currently investigating different strategic investments.

NOTE 3 – DEFERRED TAX ASSETS

The Company's tax losses can be carried forward infinitely subject to the general rules on limited deductibility due to ownership changes.

For the period ended June 30, 2025, the Company has unrecognized net tax loss carry-forwards in the Danish entity in the amount of DKK 2,212 million which is equal to a deferred tax asset of DKK 487 million as of June 30, 2025.

Statement by the Board of Directors and the Executive Management

The Board of Directors and the Executive Management have today reviewed and approved the interim financial report of Strategic Partners A/S for the period January 1 - June 30, 2025. The interim financial report has not been reviewed or audited by the Company's independent auditors.

The interim financial report for the period January 1 - June 30, 2025 has been prepared in accordance with IAS 34 Interim Financial Reporting. The accounting policies used in the interim financial report are consistent with those accounting policies used in Strategic Partners A/S's 2024 Annual Report with the additions described and additional Danish disclosure requirements for interim reports of listed companies.

In our opinion, the interim condensed financial statements give a true and fair view of Strategic Partners A/S's assets, liabilities, and financial position at June 30, 2025 and of the results of its operations and cash flows for the period January 1 - June 30, 2025.

We furthermore consider that the management's review gives a true and fair view of the development in the Group's activities and financial affairs, the profit for the period and the Group's financial position as a whole, as well as a description of the most significant risks and uncertainties to which the Group is subject.

Copenhagen, September 16th, 2025.

Board of Directors

Michael Hove Chairman of the Board

Lars Tylvad Andersen Jakob Færch Bendtsen

Executive Management

Jakob Færch Bendtsen Chief Executive Officer

Talk to a Data Expert

Have a question? We'll get back to you promptly.